- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S6400
| Related Targets | EGFR VEGFR JAK PDGFR FGFR Src FLT FLT3 HER2 Bcr-Abl |
|---|---|
| Other HIF Products | PT2399 PX-478 Dihydrochloride BAY 87-2243 KC7F2 Lificiguat (YC-1) IOX2 CAY10585 (LW 6) Molidustat (BAY 85-3934) PT2385 IDF-11774 |
|
In vitro |
DMSO
: 36 mg/mL
(200.92 mM)
Water : 36 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 179.17 | Formula | C6H13NO5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 3416-24-8 | -- | Storage of Stock Solutions |
|
|
| Synonyms | 2-amino-2-deoxy-D-glucose | Smiles | NC(C=O)C(O)C(O)C(O)CO | ||
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06200415 | Completed | Periodontal Pocket |
Ain Shams University |
November 8 2022 | Phase 2 |
| NCT05305937 | Not yet recruiting | Malignant Tumor of Breast|Benign Breast Lumps|High-Risk Breast Cancer |
Meir Medical Center|Tel Aviv University |
May 2022 | Not Applicable |
| NCT05038436 | Completed | Cholesterol Lowering |
Certmedica International GmbH|University Hospital Bonn |
September 16 2021 | Not Applicable |
| NCT03827161 | Completed | Healthy Subject|Overweight |
Fred Hutchinson Cancer Center |
August 1 2017 | Phase 1 |
| NCT03743896 | Completed | Osteoarthritis Knee |
Lynk Biotechnologies Pte Ltd|T&T Family Health Clinic and Surgery Singapore|Temasek Polytechnic School of Applied Science Singapore |
May 18 2016 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.